Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2784-2790

  Ju, Seong A ^a   Cheon, Sang Hyeon ^b   Park, Sang Min ^a   Nyuen, Quang Tam ^a   Young, Min Kim ^b   An, Won G ^c   Kim, Byung Sam ^a  

^a University of Ulsan   (South Korea)

^b Ulsan University College of Medicine   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

5 FU; Anti 4 1BB mAb; Combined therapy; Renal cell carcinoma

Indexed keywords

4 1BB MONOCLONAL ANTIBODY; FLUOROURACIL; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; FEMALE; KIDNEY CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; KIDNEY NEOPLASMS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C;

EID: 43049087388     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23457     Document Type: Article

References (40)

1. Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005;104:2323-33.
2. Dillman RO, Wiemann MC, Tai DF, Depriest CB, Soori G, Stark JJ, Mahdavi K, Church CK. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09. Cancer Biother Radiopharm 2006;21:130-7.
3. Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Marione B, Viola M, Sosman JA. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol 2002;13:606-13.
4. Fossa SD, Mickish GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, Fey M, Croies JJ, de Prijck L, Van Glabbeke M. Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004;101:533-40.
5. Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trial of interleukin 2, interferon α, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000;6:3442-50.
6. Elsasser-Beile U, Gierschner D, Weichner T, Wetterauer U. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas. Anticancer Res 2003;23:433-7.
7. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004;172:4599-608.
8. Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol 2003;22:431-7.
9. Sun Y, Chen JH, Fu Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol 2004;1:31-6.
10. Sica G, Chen L. Modulation of the immune response through 4-1BB. Adv Exp Med Biol 2000;465:355-62.
11. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol 1998;10:481-9.
12. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
13. Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, Lynch DH. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002;169:1792-800.
14. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, Tutt AL, Glennie MJ, Al-Shamkhani A. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of antitumor immune responses. Eur J Immunol 2002;32:3617-27.
15. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9.
16. Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007;27:1137-41.
17. Khosravi SP, Diaz Munoz de la Espada VM, Garcia AP, Encina GS, Izarzugaza PY, Arranz Cozar JL, Hernandez Marin B, Perez Manga G. Management of gastric adenocarcinoma. Clin Transl Oncol 2007;9:438-42.
18. Bodner-Adler B, Bodner K, Zeisler H. Breast cancer diagnosed during pregnancy. Anticancer Res 2007;27:1705-7.
19. Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. J Biol Chem 1961;236:3006-13.
20. Okamoto M, Kasetani H, Kaji R, Goda H, Ohe G, Yoshida H, Sato M. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother 1998;4:233-41.
21. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R Shu S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor reactive T-cell generation. Cancer Res 2001;61:2031-37.
22. Lissoni P, Brivio F, Fumagalli L, Di Fede G, Brera G. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo 2005;19:1077-80.
23. Claude L, Perol D, Ray-Coquard I, Petit T, Blay JY, Carrie C, Bachelot T. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005;76:334-9.
24. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
25. Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, Dong H. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 2007;179:2860-9.
26. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91.
27. + T-cell responses in tumor-bearing hosts. Cancer Res 2005;65:6984-9.
28. Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol 2001;210:56-65.
29. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003-10.
30. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998;28:1116-21.
31. Mogi S, Sakurai J, Kohsaka T, Enomoto S, Yagita H, Okumura K, Azuma M. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 2000;101:541-7.
32. Zheng G, Chen A, Sterner RE, Zhang PJ, Pan T, Kiyatkin N, Tykocinski ML. Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res 2001;61:8127-34.
33. Kocak E, Lute K, Chang X, May KF, Jr, Exten KR, Zhang H, Abdessalam SF, Lehman AM, Jarjoura D, Zheng P, Liu Y. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006;66:7276-84.
34. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006;12:693-8.
35. + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-8.
36. + T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol 2003;33:2133-41.
37. Starck L, Scholz C, Dorken B, Daniel PT. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005;35:1257-66.
38. Kim YJ, Brutkiewicz RR, Broxmeyer HE. Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells. Blood 2002;100:3253-60.
39. Ju SA, Lee SC, Kwon TH, Heo SK, Park SM, Paek HN, Suh JH, Cho HR, Kwon B, Kwon BS, Kim BS. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005;83:344-51.
40. Wilcox RA, Tamada K, Flies DB, Zhu G, Chapoval AI, Blazar BR, Kast WM, Chen L. Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 2004;103:177-84.